Physician profile

Gary Glazer

Internal Medicine · Rochester, NY

NPI 1619991338

$6,251.18

in general payments reported to CMS, 2019-2025

22 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Lilly USA, LLC $1,008.44 2019-2022
Pfizer INC. $706.45 2019-2021
Astrazeneca Pharmaceuticals LP $701.53 2019-2022
Novo Nordisk INC $654.32 2019-2022
Glaxosmithkline, LLC. $620.23 2019-2021
Janssen Pharmaceuticals, INC $467.62 2019-2022
Abbvie INC. $373.77 2019-2022
Astellas Pharma US INC $367.63 2019-2022
Boehringer Ingelheim Pharmaceuticals, INC. $334.58 2019-2022
Takeda Pharmaceuticals U.S.A., INC. $287.98 2019-2021
Merck Sharp & Dohme LLC $192.74 2019-2021
Novartis Pharmaceuticals Corporation $126.14 2019-2022
Teva Pharmaceuticals USA, INC. $98.66 2019-2022
Amgen INC. $75.59 2019-2022
Sanofi Pasteur INC. $55.93 2019
Show all 22 companies

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Gary Glazer

$6,251.18

in general payments reported 2019-2025

Years
2019-2022
Top company
Lilly USA, LLC

https://glasscript.com/doctor/254548/gary-glazer

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.